Janney Montgomery Scott LLC Acquires 789 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Janney Montgomery Scott LLC boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 9.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,427 shares of the biotechnology company’s stock after buying an additional 789 shares during the quarter. Janney Montgomery Scott LLC’s holdings in United Therapeutics were worth $3,326,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of UTHR. World Investment Advisors LLC bought a new position in shares of United Therapeutics in the 3rd quarter worth $139,206,000. FMR LLC grew its stake in United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after purchasing an additional 314,004 shares during the last quarter. Assetmark Inc. raised its holdings in United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after buying an additional 123,929 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec boosted its holdings in shares of United Therapeutics by 32.5% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 343,744 shares of the biotechnology company’s stock valued at $123,181,000 after buying an additional 84,369 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of several recent analyst reports. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. The Goldman Sachs Group boosted their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. Finally, TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $378.36.

United Therapeutics Trading Down 0.3 %

Shares of NASDAQ:UTHR opened at $351.17 on Friday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The company has a market cap of $15.68 billion, a PE ratio of 15.42, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57. The company’s 50 day moving average is $365.03 and its 200 day moving average is $356.94.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.38 earnings per share. Equities research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Activity

In other United Therapeutics news, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the transaction, the director now owns 5,655 shares of the company’s stock, valued at approximately $2,332,574.40. The trade was a 23.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 15,000 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $407.32, for a total transaction of $6,109,800.00. The disclosure for this sale can be found here. Insiders sold a total of 133,838 shares of company stock valued at $50,445,556 in the last quarter. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.